News

CURE2d
FDA Approves Emrelis in Previously Treated, Advanced NSCLC
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...
The American Journal of Managed Care1d
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...
STAT8d
FDA approves Verastem’s ovarian cancer treatment
Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...
Cancer Therapy Advisor1d
FDA Approves Emrelis for High c-Met Protein Overexpressing NSCLC
The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.
The American Journal of Managed Care8d
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...
WebMD15d
FDA Approves New Long-Term Treatment for Myasthenia Gravis
May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...
pharmaphorum2d
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment
Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new ... two new antiretroviral treatment options, Delstrigo and ...
Yahoo Finance17d
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of ...